From: PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Trial name | Study drug | Patient population | Primary outcome measure | Follow-up |
---|---|---|---|---|
FOURIER NCT01764633 | Evolocumab | n = 27,000; history of CVD – at high risk of recurrent event; LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL; background statin therapy | Time to cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization | 5 years |
ODYSSEY OUTCOMES NCT01663402 | Alirocumab | n = 18,000; acute coronary syndrome <52 weeks earlier; LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL; background statin therapy | Time to cardiovascular death, non-fatal myocardial infarction, hospitalization for unstable angina, or stroke | 64 months |
SPIRE-1 NCT01975376 | Bococizumab | n = 17,000; high risk of CVD event, primary and secondary prevention; background lipid-lowering treatment; LDL-C 70–100 mg/dL or non-HDL-C 100–130 mg/dL | Time to composite major cardiovascular event (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina) | 60 months |
SPIRE-2 NCT01975389 | Bococizumab | n = 9000; high risk of CVD event; background lipid-lowering treatment; LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL | Time to composite major cardiovascular event (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina) | 60 months |